文献速递淋巴瘤

重新定义依托泊苷在外周T细胞淋巴瘤一线治疗中的作用

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma.
PubMed 文献 · Blood Adv · 2017-10-27

基于韩国国家健康保险服务与国家癌症登记处合并数据,共1933例外周T细胞淋巴瘤患者(中位年龄58岁)接受分析,38%接受CHOP或CHOP样方案,35.1%接受CHOP样方案联合依托泊苷。按方案分为3组后,第1组(CHOP或CHOP样方案)与最长无进展生存期(P<.001)和总生存期(P<.001)相关,且该无获益在不同亚型和年龄组中一致。

要点

  • 在CHOP样方案中加入依托泊苷未改善外周T细胞淋巴瘤患者的PFS或OS。
  • 第1组(CHOP或CHOP样方案)与最长PFS(P<.001)和OS(P<.001)相关。
  • 加用依托泊苷导致住院时间延长和需更多输血的细胞减少。

核心结论

  • 在CHOP样方案中加入依托泊苷未给外周T细胞淋巴瘤患者带来更好的PFS或OS。
  • 总体而言,亚洲外周T细胞淋巴瘤患者未从一线化疗强化中获益。

研究设计与样本

  • 使用韩国国家健康保险服务与国家癌症登记处的合并数据,共评估1933例患者(中位年龄58岁)的临床特征和治疗结局。

主要发现

  • 1933例患者中,38%(n=748)接受CHOP或CHOP样方案,35.1%(n=678)接受CHOP样方案联合依托泊苷,5.9%(n=113)接受其他骨架化疗联合依托泊苷,20.3%(n=394)接受其他一线治疗。
  • 按方案分为3组(第1组:CHOP或CHOP样方案;第2组:CHOP或CHOP样方案联合依托泊苷;第3组:所有其他),第1组与最长无进展生存期(PFS;P<.001)和总生存期(OS;P<.001)相关。
  • 加用依托泊苷无获益这一现象在不同外周T细胞淋巴瘤亚型和年龄组中均被观察到。
  • 加用依托泊苷导致住院时间延长和需更多输血的细胞减少。
  • upfront造血干细胞移植带来更好的OS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphomas (PTCLs) have an aggressive biological course and poor clinical outcomes. Despite producing somewhat less-than-satisfactory results, the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remains the de facto standard in PTCL treatment. Addition of etoposide to CHOP backbone to overcome such unsatisfactory results has yielded contradictory information. We aimed to thoroughly analyze the impact of incorporating etoposide into first-line treatment. Using merged data from the Korean National Health Insurance Service and National Cancer Registry, a total of 1933 patients (median age, 58 years) were evaluated for clinical characteristics and treatment outcomes. Thirty-eight percent (n = 748) of the 1933 patients received CHOP or CHOP-like regimen, 35.1% (n = 678) received CHOP-like regimen plus etoposide, 5.9% (n = 113) received other backbone chemotherapy plus etoposide, and 20.3% (394) received other treatments in the first-line setting. When we divided the patients into 3 groups according to regimen (group 1, CHOP or CHOP-like regimen; group 2, CHOP or CHOP-like regimen plus etoposide; group 3, all others), group 1 was associated with longest progression-free survival (PFS; P < .001) and overall survival (OS; P < .001). This lack of benefit with etoposide addition was observed across different PTCL subtypes and age groups. Adding etoposide led to longer hospitalizations and cytopenias requiring more transfusion. Upfront hematopoietic stem-cell transplantation led to better OS. Addition of etoposide to CHOP-like regimens does not result in better PFS or OS for patients with PTCL. Overall, Asian patients with PTCL do not benefit from chemotherapy intensification of first-line treatment. We hereby provide crucial information on establishing standardized PTCL treatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kim YA, Byun JM, Park K, et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv. 2017. PMID: 29296861. doi:10.1182/bloodadvances.2017010819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。